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IN a previous communication (Cohen and Cohen, 1954b) it was noted that
tumours arising from viable grafts of the C3H mammary carcinoma, which had
been attenuated by sublethal doses of radiation immediately before implantation,
were found, when subsequently irradiated in situ, to have a significantly increased
radiosensitivity. The radiosensitization didnot appear to be due to anypermanent
change in the tumour, or to any local reaction in the tumour bed, but could be
explained only on the basis of a subliminal systemic resistance mechanism,
possibly in the nature of a circulating iso-antibody arising in the host. If this
postulate is correct, it might be possible to enhance the radio-sensitivity of an
established non-attenuated isograft by inoculation of the host with a suitably
attenuated second implant. The present investigation demonstrates that
induced radiosensitization of an isogenic tumour in inbred mice is feasible, and
may possibly point the way to more efficient therapy of autogenous growths.
The procedure is complicated by additional variables not encountered when
the radiation-attenuated homografts themselves are treated. The attenuation
doses can vary widely, and may include a higher dosage range where the irradiated
inocula no longer "take ". One may also choose almost any interval between
implantation of the unmodified tumour and the inoculation of the irradiated
fragment. Further, the time between the dates of implantation of the attenuated
inoculum and ofthe treatment in situ ofthe established tumour may vary widely.
The present experiment, therefore, is designed firstly to explore the possibility of
radiosensitization of an unmodified transplanted C3H mammary adenocarcinoma
by means of an attenuated tumour inoculum, and secondly to seek effective
combinations of timing and dosage factors for this type of procedure.
MATERIALS AND METHODS
Experimental design
Young adult male mice from the C3H/Cg substrain were used. Each received
two inoculations: one consisting of fragments of an unmodified inoculum, that
is the usual isogenic C3H mammary tumour homoplast, into the right flank, and
the second an attenuated inoculum, tumour fragments irradiated in vitro prior
to implantation, into the left flank. After a suitable period, depending on the
experimental variables, the unmodified tumour was irradiated in situ using the
standard procedure. It was considered that the following variables might affectRADIOSENSITIVITY AND ISOGRAFTS
results sufficiently to warrant analysis: the attenuation dose, the interval between
inoculation of the attenuated implant and of the unmodified tumour, and the
interval between inoculation of the attenuated implant and irradiation of the
unmodified tumour.
Since the immediate object of this investigation was merely to select, from
manypossiblepermutations, afairlyeffectiveradiosensitizingprocedure, acomplete
probit assay was not attempted, but as each unmodified inoculum reached a size
ofabout 1 cm. in diameter, it was irradiated in situ with a standard dose of 4200r.
This quantity was chosen since the expectation of cure at this dose is normally
under 0.1 per cent, but it nevertheless affords very significant cure-rates in those
instances when some degree ofhost resistance operates against the tumour (Cohen
and Cohen, 1954a). Concurrently, in a control series of 97 mice, each bearing a
single unmodified isograft treated at the same dose, no cures were in fact observed.
Irradiation technique
As in all previous experiments of this series, rbntgen rays generated at 240
kVp., no added filters, HVL 0.34 mm. Cu., FSD 25 cm., were used. For irradiation
in situ, a 2 cm. diameter field, directed through the tumour retracted on to a wax
block, gave a dose rate of 500r/min. The attenuation procedure was carried out
by irradiation ofminced tumour fragments in a plastic welled slide with the same
technical factors but using a 5 cm. diameter field giving 600r/min. with full back-
scatter, as described in our previous communication (Cohen and Cohen, 1953).
Attenuation of the tumour
Using the technique described above, a fairly wide range ofdosage from 2500r
to 5000r was tested, but for the purpose of analysis, the attenuated inocula were
grouped into the two categories shown in Table I, according to their ability to
"take " subsequently. In the dose range 2500r to 3000r, the majority of the
attenuated implants were viable and grew readily after a moderately prolonged
latent period, while in the 3500r to 5000r range, the growth of almost all implants
was arrested. Although most implants in the upper range of attenuation dosage
do not "take ", there is nevertheless no reason to believe that they are inviable
(Cramer, 1932; Goldfeder, 1940), so the terms "viable" or "arrested " will here
be used to describe attenuated inocula which "take" or fail to "take" respec-
tively. In the case ofviable inocula, there is the additional complication that the
attenuated tumour has to be removed eitherby excision or irradiation ifthe animal
is to survive long enoughfortheunattenuatedtumourto be observed andfollowed.
It has become necessary, in the light of the larger number of attenuations in
the present series to revise our 1953 estimate of the LD50 for irradiation in vitro.
The variation among different batches of attenuated tumour has now been found
to be much larger than that among individual mice inoculated with the same
batch of tumour tissue. Individual "takes" within each group were therefore
not stochastically independent of one another, so that each batch of irradiated
tumour afforded only one degree of freedom instead of 10 to 15 as previously
assumed, giving a standard error much larger than that reported. While not
affecting any conclusions drawn (Cohen and Cohen, 1954c), the corrected LD50
for irradiation prior to implantation now appears to be 3200 (+ 125)r, instead of
2850r as originally reported (Cohen and Cohen, 1953). In general, the tumour
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remained viable when attenuated with doses smaller than this median value, and
was arrested by larger doses.
Timing procedures
While the interval between the attenuated and unmodified inocula could be
deliberately selected, the time elapsing between inoculation and treatment was
not easily controlled and varied widely. Four different attenuation-timing factors
were tested: the attenuated inoculum (A.I.) being given 3 weeks before, 3 days
before, 3 days after, or 3 weeks after the unmodified inoculum (U.I.), that is, U.I.-
A.I. intervals of - 21, - 3, + 3, and + 21 days respectively as shown in Table
I. The time intervals between the implantation of the attenuated inoculum and
irradiation ofthe unmodified tumour in situ could not be limited to set standards,
and ranged from 3 to 60 days, according to the time ofinoculation and the tumour
growth rates. The last four columns ofTable I show the range ofthis variable and
the median values for cured and non-cured mice in each category.
RESULTS
In Table I the results of several individual experiments, in which all tumours
were treated with 4200r, are summarized. Inthethreegroups where the attenuated
inoculum was given before the unmodified tumour graft, there was no response to
treatment at this dose level. On the other hand, when the attenuated inoculum
followed the unmodified implant, the same dose resulted in 26 cures among 92
mice treated, assessed 3 months after irradiation. There seems to be no significant
difference between the 3-day and the 21-day U.I.-A.I. interval, given the correct
order of inoculation. It is also noted that mice receiving isografts attenuated at
3500 to 5000r, which did not subsequently "take ", showed a much higher cure
rate (19/38) than those which had received inocula of viable attenuated tumour
(7/54). In 28 of the 54 mice bearing bilateral tumours, the attenuated "take"
appeared only after it had become obvious that the unattenuated tumour was not
responding to treatment, so that no further intervention was necessary. In 15
cases, of which 4 were cured, the attenuated inoculum was surgically excised
between 3 and 26 days after treatment of the unmodified tumour. In 11 cases
the attenuated "take " was irradiated with 4200r in situ either at the time of
treatment of the unmodified tumour, or from 3 to 29 days thereafter; 3 of these
mice were bilaterally cured. There seemed to be no obvious difference in timing
between the 7 cured and the 19 recurrent cases in these groups. The greater
proportion of cures occured when the interval between the attenuated inoculum
and the treatment in situ of the unmodified tumour was in the region of 4 to 5
weeks, the effective period apparently being not less than 2 weeks and continuing
up to about 7 weeks.
Comparing the 3-month result for this whole experimental series (26/123) cures
with the observed control series treated at the same dose (0/97 cures) indicates a
highly significant increased radiocurability at the probability level p < 0.00001.
Over half of the 3-month cures developed late recurrences, a phenomenon not
previously observed in this series of experiments. In order to complete the data,
therefore, it was necessary to continue follow-up on treated animals, whenever
possible, for at least 6 months. Accordingly, both 3-month and 6-month results
are shown in Table I; the former give a useful comparison with previous experi-
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TABLE I.-Effect of Inoculation of the Host with Radiation-attenuated Homologous
Tumour Tissue on the Radiosensitivity ofthe C3H Mouse Mammary Carcinoma
Treated in situ with 4200r.
Cure rates ofunmodified tumours
when attenuated implants are:
(a) Viable (b) Arrested Cure rates after 4200r. Attenuated inoculum to
Inocula Inocula ^ treatment intervals (days).
(2500-3500r). (3500-5000r). (At 3 months) (At 6 months) , -
U.I.-A.I.* ,---- v · Cures. Non-cures.
interval. No. No. No. No. Per Per f----A-- -
(Days.) of mice. cured. of mice. cured. Total. cent. Total. cent. Range. Median.Range.Median.
-21 . 10 0 - - .0/10 0 - - . - 44-50 47
- 3 . 10 0 11 0 . 0/21 0 -. 21-60 43
+ 3 . 34 7 28 15 . 22/62 36 8/62 13 . 14-52 35 14-45 40
+21 . 20 0 10 4 . 4130 14 2/30 7 . 17-34 28 3-34 7
Total . 74 7 49 19 .26/123 21
Significant at p < 00001
Controls . No attenuation . 0/97 0 J
* U.I. = Unmodified, non-attenuated tumour inoculum.
A.I. = Radiation-attenuated tumour inoculum; see text.
ments ofthis series in which results were finally assessed at 3 months, and the latter
serve to indicate the absolute curability ofthe tumour under the conditionsoftjhe
presentexperiment. Therewerenorecurrences laterthan 6monthsaftertreatment.
There were no obvious differences in timing or technique to account for the long-
term cures except that they were confined to those mice in which the attenuated
inocula had remained arrested, all ofthe 7 mice "cured" at 3 months but having
viable attenuated inocula developing late recurrences.
From the information available in Table I, it would seem that optimal effects
are obtained when attenuated isografts are irradiated in vitro with arresting doses
inthe 3500to 5000rrange, andinoculated between 3 and 21 days afterimplantation
of the unmodified tumour graft, and a period of 2 to 7 weeks allowed to elapse
before treatment in situ. The cure rate, assessed at 3 months, then approaches
50per cent compared with an expectation ofonly 0.1 per cent in the corresponding
controls.
DISCUSSION
It has been shown that a significant increase in radiosensitivity appears,
firstly, when a tumour which has arisen from an implant attenuated with radiation
immediatelypriortoinoculationis irradiatedinsitu, andsecondly, in the treatment
of unmodified tumours growing in hosts who have been inoculated concomitantly
with an attenuated fragment of the same tumour. While the former category is
of limited academic interest, the second effect is of more practical importance
in that induced radiosensitization of established tumours may have possible
clinical applications.
The cure rate attained in the case of such indirectly radiosensitized tumours is
of the same order as that previously reported for directly attenuated tumour
inocula treated at the same dose, at best about 50 per cent cures at 4200r. ItA. COHEN AND L. COHEN
seems probable that a similar mechanism operates in the two cases. Previous
observations (Cohen and Cohen, 1954b, 1954c) suggestedthat the attenuated tissue
had been rendered antigenic to the host, thus evoking some generalized systemic
resistance mechanism, most probably a circulating iso-antibody. These subliminal
immune reactions are apparently regularly associated with an increased radio-
sensitivity of the tumour (Cohen and Cohen, 1954a). The results of the present
experiment follow logically from, and lend strong support to this immunological
hypothesis.
The tendency to late recurrence in many of the initially cured mice has not
been previously observed in this laboratory, although a very large series of cured
mice has now accumulated from many preceding experiments. It seems that the
apparently cured tumours are not entirely eradicated by irradiation in situ, at
least at this relatively ineffective dose level, but are subject to some continuing
restraint or resistance on the part of the host. The phenomenon of prolonged
tumour dormancy associated with host resistance, and recrudescence when this
resistance fails, is also well-known in clinical cancer (Hadfield, 1954). The restrain-
ing process, perhaps the titre ofthe antibody, in common with most other immuno-
logical responses, tends to diminish with time, thus permitting late, slow-growing
recurrences of tumours that were impalpable for some 3 months after treatment.
Iftheforegoing results are to be explained on an immunological hypothesis, then
more effective immunizing procedures are likely to give still better responses. In
line with past experience in immunology it may well be that animals bearing
primarily unmodified tumours, to which they normally have little or no resistance,
mnay require repeated "booster" inocula of attenuated tissue to maintain the
remission. It is possible, too, that tumour tissue attenuated at doses higher than
those used in the above experiments would be more effective, as the observed
trend towards greater curability with larger attenuating doses was not fully
explored.
SUMMIIARY
C3H mice bearing isografts of the C3H mammary adenocarcinoma were
inoculated with fragments of the same tumour that had been attenuated with
varying doses of rontgen rays immediately prior to implantation. The originally
established tumours were then irradiated in situ with 4200r, a dose at which the
expectation of cure is normally under 01 per cent. In this experimental series,
however, the cure rate at 4200r approached 50 per cent, indicating that the
procedure had significantly increased the radio-sensitivity of the unmodified
isogenic tumour. Optimal results were obtained when the attenuation dose was
5000r, the interval between implantation of the unmodified tumour and the
attenuated inoculum was 3 to 21 days, and the interval between the attenuated
inoculum and treatment in situ was 2 to 7 weeks.
A tendency to late recurrence was noted in some of these tumours apparently
cured for 3 months after treatment.
It is considered that inoculation of the attenuated tumour fragment induces
a subliminal and transient resistant state in the host, which enhances the radio-
sensitivity of a previously established tumour.
The authors are deeply indebted to Dr. J. F. Murray, of the South African
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facilities for the maintenance of the animals used in these experiments, and to
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